Next Article in Journal
Heat-killed VSL#3 Ameliorates Dextran Sulfate Sodium (DSS)-Induced Acute Experimental Colitis in Rats
Previous Article in Journal
Necrostatin-1 Attenuates Ischemia Injury Induced Cell Death in Rat Tubular Cell Line NRK-52E through Decreased Drp1 Expression
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2014, 15(1), 1-14;

Effect and Mechanism of Mitomycin C Combined with Recombinant Adeno-Associated Virus Type II against Glioma

School of Life Science, Beijing Institute of Technology, Haidian District, Beijing 100081, China
These authors contributed equally to this work.
Authors to whom correspondence should be addressed.
Received: 29 July 2013 / Revised: 9 December 2013 / Accepted: 9 December 2013 / Published: 19 December 2013
(This article belongs to the Section Biochemistry)
Full-Text   |   PDF [1617 KB, uploaded 19 June 2014]


The effect of chemotherapy drug Mitomycin C (MMC) in combination with recombinant adeno-associated virus II (rAAV2) in cancer therapy was investigated, and the mechanism of MMC affecting rAAV2’s bioactivity was also studied. The combination effect was evaluated by the level of GFP and TNF expression in a human glioma cell line, and the mechanism of MMC effects on rAAV mediated gene expression was investigated by AAV transduction related signal molecules. C57 and BALB/c nude mice were injected with rAAV-EGFP or rAAV-TNF alone, or mixed with MMC, to evaluate the effect of MMC on AAV-mediated gene expression and tumor suppression. MMC was shown to improve the infection activity of rAAV2 both in vitro and in vivo. Enhancement was found to be independent of initial rAAV2 receptor binding stage or subsequent second-strand synthesis of target DNA, but was related to cell cycle retardation followed by blocked genome degradation. In vivo injection of MMC combined with rAAV2 into the tumors of the animals resulted in significant suppression of tumor growth. It was thus demonstrated for the first time that MMC could enhance the expression level of the target gene mediated by rAAV2. The combination of rAAV2 and MMC may be a promising strategy in cancer therapy. View Full-Text
Keywords: recombinant adeno-associated virus II; mitomycin C; glioma recombinant adeno-associated virus II; mitomycin C; glioma
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Ma, H.; Zhang, Y.; Wang, H.; Han, C.; Lei, R.; Zhang, L.; Yang, Z.; Rao, L.; Qing, H.; Xiang, J.; Deng, Y. Effect and Mechanism of Mitomycin C Combined with Recombinant Adeno-Associated Virus Type II against Glioma. Int. J. Mol. Sci. 2014, 15, 1-14.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top